NASP Submits Comments to CMS

WASHINGTON, DC (July 23, 2020) – The National Association of Specialty Pharmacy (NASP) recently submitted comments on the Center for Medicare and Medicaid Services’ (CMS) proposed rule, “Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered Under in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements” at 85 Fed. Reg. 37286 et seq.

The proposed rule is intended to promote transparency, flexibility and innovation in drug pricing through new regulatory policies to assist manufacturer and state participation in value-based payment (VBP) arrangements while maintaining the integrity of the Medicaid Drug Rebate Program. The proposed rule would also revise regulations concerning pharmacy manufacturer copay assistance programs and PBM accumulator programs.

NASP submitted recommendations on sections of the rule to specifically address the needs of specialty patients and the pharmacies that serve their needs. To read the comments, please click here.